Skip to content

Anika Therapeutics ANIK Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Net margin-9.8%+43.3pp-9.9%+36.6pp-40.2%+19.2pp-65.1%-20.6pp-53.1%-7.7pp
Returns
Return on equity-8%+23.8pp-7.5%+23.3pp-20.2%+23.1pp-33.9%-3.2pp-31.8%-0.2pp
Efficiency
Asset turnover0.6×+0.2×0.6×+0.1×0.4×-0.2×0.4×-0.2×0.5×-0.1×
Liquidity
Current ratio4.5×-1.3×4.7×-0.2×5.3×0.0×6.2×+0.2×5.7×+0.1×
Leverage
Debt-to-equity0.2×0.0×0.2×0.0×0.2×0.0×0.2×0.0×0.2×0.0×
Valuation
Market capitalization$204.37M+31.6%$138.59M-42.5%$135.53M-62.9%$161.05M-56.4%$213.07M-43.5%
Price / sales1.8×+0.1×1.2×-0.8×1.6×-0.6×1.7×-0.5×-0.2×
Price / book1.5×+0.5×-0.6×0.9×-1.1×1.1×-0.7×1.4×-0.4×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Anika Therapeutics's ratios come from?
Every ratio is computed from Anika Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.